NCT06697353View on ClinicalTrials.gov

An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan

CompletedOBSERVATIONAL
Enrollment

4,936

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

September 19, 2025

Study Completion Date

September 19, 2025

Conditions
Chronic Heart FailureChronic Heart Failure With Reduced Ejection Fraction
Interventions
DRUG

vericiguat (BAY 1021189)

2.5 mg initiating dose

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06697353 - An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan | Biotech Hunter | Biotech Hunter